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Abstract
Introduction Acquired demyelinating syndromes (ADS) are immune-mediated demyelinating disorders of the central nerv-
ous system in children. A nationwide, multicentre and prospective cohort study was initiated in the Netherlands in 2006, 
with a reported ADS incidence of 0.66/100,000 per year and MS incidence of 0.15/100,000 per year in the period between 
2007 and 2010. In this study, we provide an update on the incidence and the long-term follow-up of ADS in the Netherlands.
Methods Children < 18 years with a first attack of demyelination were included consecutively from January 2006 to Decem-
ber 2016. Diagnoses were based on the International Paediatric MS study group consensus criteria. Outcome data were 
collected by neurological and neuropsychological assessments, and telephone call assessments.
Results Between 2011 and 2016, 55/165 of the ADS patients were diagnosed with MS (33%). This resulted in an increased 
ADS and MS incidence of 0.80/100,000 per year and 0.26/100,000 per year, respectively. Since 2006 a total of 243 ADS 
patients have been included. During follow-up (median 55 months, IQR 28–84), 137 patients were diagnosed with mono-
phasic disease (56%), 89 with MS (37%) and 17 with multiphasic disease other than MS (7%). At least one form of residual 
deficit including cognitive impairment was observed in 69% of all ADS patients, even in monophasic ADS. An Expanded 
Disability Status Scale score of ≥ 5.5 was reached in 3/89 MS patients (3%).
Conclusion The reported incidence of ADS in Dutch children has increased since 2010. Residual deficits are common in 
this group, even in monophasic patients. Therefore, long-term follow-up in ADS patients is warranted.
Keywords Children · Multiple sclerosis · Acquired demyelinating syndromes · Epidemiology · Outcome
Introduction
Acquired demyelinating syndromes (ADS) are immune-
mediated demyelinating disorders of the central nervous 
system (CNS) in children [1, 2]. ADS encompass a wide 
spectrum of neurological symptoms depending on the loca-
tion of inflammation and the severity of demyelination. As 
the clinical symptoms overlap in this spectrum, international 
consensus criteria have been proposed in 2007 to aid in diag-
nosis and distinction between subtypes [3]. These criteria 
were revised in 2012 [4]. In addition, new findings in the 
past few years added valuable insights into paediatric ADS 
and its subtypes, including the identification of new bio-
markers such as anti-myelin oligodendrocyte glycoprotein 
antibodies (MOG-ab) [2, 5] and the identification of new 
clinical subtypes as acute disseminated encephalomyelitis 
followed by optic neuritis (ADEM-ON) [6].
ADS may remain monophasic after the first event. Yet, 
15–32% of these children will fulfil the diagnostic criteria 
for paediatric MS within 5 years after the initial attack [1, 2, 
7, 8]. Multiple aspects of outcome of paediatric MS patients 
have been described before, including the rate of disease 
progression in Expanded Disability Status Scale (EDSS) 
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scores [9, 10], cognitive performance [11–13], decreased 
motor performance [14, 15], and neuropsychiatric com-
plaints like fatigue and mood disorders [14, 16]. However, 
studies describing the long-term outcome of other ADS sub-
types are scarce.
In the Netherlands, a multicentre and prospective study 
was established in 2006 with national coverage for children 
with a first demyelinating event. Incidence estimates of pae-
diatric ADS and multiple sclerosis have been reported in 
our prior work for the period between 2007 and 2010 [17]. 
However, the number of patients who will be diagnosed 
with MS will likely increase with longer follow-up time. 
Furthermore, an increasing MS incidence in children has 
been reported in specific regions [18, 19]. Therefore, we aim 
to re-assess the incidence and presenting characteristics of 
ADS and its subtypes in the Netherlands. Second, we aim to 
provide long-term follow-up data of the patients included in 
our prospective and multicentre cohort in the Netherlands.
Methods
Patient inclusion
Children younger than 18 years, residing in the Nether-
lands, and experiencing a first inflammatory demyelinating 
event of the CNS in the period from 2006 to 2016 have been 
included in this study. All patients are participants of the 
PROUD-kids study (PRedicting the OUtcome of a Demy-
elinating event in children), a prospective, multicentre and 
observational cohort study. Paediatric neurologists of the 
eight Dutch academic hospitals and of ten non-academic 
hospitals took part in this study and included patients to 
reach nationwide coverage.
Diagnoses were made using the revised criteria proposed 
by the International Pediatric Multiple Sclerosis Study 
Group (IPMSSG) [4]. Patients with alternative diagnoses 
were excluded (e.g. systemic autoimmune diseases, infec-
tious diseases or metabolic diseases). Patients were classi-
fied as neuromyelitis optica spectrum disorder (NMOSD) 
as presenting phenotype if either patients were tested sero-
positive for anti-aquaporin 4 antibodies (AQP4-ab), or when 
AQP4-ab-negative patients presented with simultaneous 
optic neuritis (either unilateral or bilateral) and transverse 
myelitis (TM) with at least three segments.
Baseline parameters
At inclusion, demographic and clinical information of each 
patient was gathered. Demographic characteristics consisted 
for example of ethnic background, date and place of birth 
and family history on familial autoimmune diseases. Clinical 
characteristics consisted of presenting symptoms, reported 
infection or vaccination in the preceding 4 weeks, acute 
treatment and hospitalization. MRI images, serum and CSF 
parameters were also reviewed when available for diagnos-
tics or evaluation.
Follow‑up parameters
If patients were not referred to the paediatric MS centre for 
follow-up, the follow-up data of the patients were provided 
by the treating physician (e.g. clinical letters) and by inter-
viewing the parents through telephone every 2 years after 
disease onset.
Cognitive impairment (CI) and residual neurological defi-
cits were assessed using the most recent neuropsychological 
assessment (NPA) performed by a paediatric clinical neu-
ropsychologist, and neurological examination by a paediatric 
neurologist. NPAs were being performed appropriately for 
age. During the NPA, at least six of the following cogni-
tive domains were being assessed for the presence of cog-
nitive deficits: behaviour, language, intelligence, attention 
and concentration, memory, executive control functions and 
visuospatial abilities. Children were classified as cognitive 
impaired if at least one of these domains was affected.
If data on neurological examination or NPA were not 
available, a standardized questionnaire was administered 
asking parents or patients about the presence of sensory 
complaints, motor deficits (e.g. complaints regarding pare-
sis, ataxia, balance problems), bladder complaints (e.g. 
urge incontinence), maximum walking distance and cog-
nitive impairment (including negatively affected school 
performance).
The Expanded Disability Status Scale is widely used to 
express disability of patients with MS diagnosis [20]. EDSS 
5.5 stands for a walking distance of maximum 100 m, with-
out aid or rest.
Antibody testing
Serum AQP4-ab and MOG-ab were tested with cell-based 
assays (CBA) provided in a central laboratory as described 
previously [21, 22]. Patients were tested for regular diag-
nostics, or retrospectively when serum of the patient was 
still available.
Ethics approval
This study was approved by the Medical Ethical Committees 
of the Erasmus MC in Rotterdam and the other participating 
centres. Written informed consent was obtained from parents 
and also from patients if aged > 12 years at presentation.
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Statistical analysis
Demographic data of the general Dutch population were pro-
vided by Statistics Netherlands [23]. These data were used to 
calculate the incidence of ADS and its subtypes in the period 
of 2011–2016 in the Netherlands. Statistical analyses were 
performed using IBM SPSS 21. Figures were made using 
Graphpad Prism 5.
Chi-square and when appropriate Kruskal–Wallis tests 
were used to test differences in demographic and clinical 
characteristics between the different subtypes. For differ-
ences in numerical data between subtypes the ANOVA test 
was used, and when necessary the Mann–Whitney U test. 
To compare the ethnic background of the patients with the 
Dutch population we used a Z test, with data provided by 
Statistics Netherlands [23]. Results were considered sig-
nificant if p < 0.05. Missing data were removed from the 
analyses in all subgroups.
Results
Incidence
From January 1, 2011 to December 31, 2016, 165 ADS 
patients were reported of which 55 (33%) received an 
MS diagnosis during FU. In this period, the incidence of 
ADS was 0.80/100,000 per year, ADEM incidence was 
0.23/100,000 per year and MS incidence was 0.26/100,000 
per year. An overview of the calculated incidences is shown 
in Fig. 1.
First presentation of ADS
From January 1, 2006 to December 31, 2016, 353 patients 
were eligible. Of these patients, 243 patients with a first 
demyelinating event were included in the study (Fig. 2). 
Presenting phenotypes consisted of optic neuritis (ON; n = 
55, 23%; from which 16/55 bilateral ON, 29%), transverse 
myelitis (TM; n = 23, 9%); other monofocal clinically iso-
lated syndromes (CIS; n = 37, 15%), polyfocal CIS (n = 47, 
19%), acute disseminated encephalomyelitis (ADEM; n = 70, 
29%) and NMOSD (n = 11, 5%).
Regarding the age of onset, children with ADEM were 
significantly younger than the other presenting phenotypes 
(p < 0.001) and presented more often after a reported preced-
ing infection (p < 0.001). The latter also applied to children 
who experienced a TM as first event (p = 0.01).
The ratio between females and males in all ADS patients 
did not differ significantly between the presenting pheno-
types. When the ADS patients are divided into a group 
aged < 11 years (n = 104) and a group > 11 years (n = 139), 
the female:male ratio differed significantly (1.02:1 versus 
1.76:1, p = 0.04).
Seventy-eight patients (32%) were of non-Caucasian ori-
gin. This proportion was significantly higher than the pro-
portion of children of non-Caucasian origin (17%) in the 
general paediatric population in the Netherlands (Z = 5.1, 
p < 0.001) [23]. Most of the non-Caucasian patients were of 
African (29%) or Middle-eastern (23%) ethnicity.
Forty-eight percent of all patients had a positive famil-
ial history of autoimmune diseases (first- and second-grade 
family members). Forty-eight (20%) patients reported the 
presence of rheumatoid arthritis in their family, 40 (16%) 
reported thyroid diseases, 35 (14%) the presence of other 
autoimmune diseases (e.g. Wegener’s disease and Crohn’s 
disease), 15 (6%) the presence of MS, 14 (6%) diabetes mel-
litus type 1 and 4 (2%) the presence of optic neuritis (ON). 
No significant difference was observed between the present-
ing phenotypes considering the familial history (p = 0.3).
In all ADS patients, disease onset in winter was most 
prevalent (32%), compared to spring (28%), summer (22%) 
and autumn (17%). MOG antibodies were found to be posi-
tive in 31 of the 146 tested patients (21%). When compar-
ing the presenting phenotypes, MOG antibodies were most 
frequently found in patients who presented with ADEM and 
NMOSD (p < 0.001).
Detailed patient characteristics are displayed in Table 1.
Follow‑up
For the follow-up analysis, we divided all patients into the 
following categories: monophasic disease, MS and mul-
tiphasic non-MS disease (Table 2). The median follow-up 
time of all patients was 55 months (IQR 28–84).
Monophasic patients
One hundred and thirty-seven patients remained mono-
phasic (137/243, 56%), including ADEM (n = 62, 45%) 
Fig. 1  Incidence of acquired demyelinating syndromes (ADS) and 
multiple sclerosis (MS) in the Netherlands in 2007–2010 and 2011–
2016
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ON (n = 27, 20%; from which 11/27 bilateral ON, 41%), 
TM (n = 17, 12%), CIS (n = 7, 5%), polyfocal CIS (n = 16, 
12%), and monophasic NMOSD (n = 8, 6%). Of these 
NMOSD patients, three were tested seropositive for 
AQP4-ab and four were seropositive for MOG-ab. Seven 
monophasic patients received chronic immunosuppres-
sive therapy: this was initiated in all AQP4-ab-positive 
patients, and in one of the MOG-ab-positive patients due 
to the disease severity at onset (Table 2). Two CIS patients 
received disease-modifying treatment (DMT) because of 
suspected risk of future MS. One patient had a LETM that 
required ICU admission and ventilation, and was, there-
fore, given chronic immunosuppressive therapy for 1 year.
MS patients
Eighty-nine patients were diagnosed with MS in our 
cohort (37%), of which 87 received the diagnosis within 
5 years of follow-up. Of the 89 MS patients, 70 individu-
als developed a second attack during follow-up, and were 
thus diagnosed with clinically definite MS (CDMS). In 
these patients, the median time to CDMS was 9 months 
(IQR 4–27). After 2 years of follow-up, 74 percent of the 
MS patients developed CDMS. No patients with MS had a 
primary progressive disease course. Only one MS patient 
had an ADEM as first presentation. After dividing the MS 
patients into two groups, aged over or below 11 years, the 
sex ratio showed a trend towards significance (p = 0.07), 
with more girls in the older MS group.
Compared to monophasic ADS, patients who received 
MS diagnosis during follow-up were more often of non-
Caucasian origin (p < 0.001) (Table 2). The calculated 
MS incidence for patients of non-Caucasian origin was 
0.78/100,000 per year in the period from 2011 to 2016, 
compared to 0.16/100,000 per year in children of Cauca-
sian origin.
At last follow-up, 73/89 MS patients were on DMT for 
the duration of at least 1 year and in 28 patients second-
line treatment was started (Table 2). Of these 28 patients, 
22 started using second-line treatment because of high MS 
activity, either on MRI or clinically, five because of side 
effects of first-line treatment and one due to the participa-
tion in an international paediatric MS drug trial.
Multiphasic non‑MS patients
The patients with multiphasic non-MS disease consisted 
of five patients who were diagnosed with ADEM-ON, five 
with NMOSD (AQP4 n = 2, MOG n = 1), four with recurrent 
ON, two with multiphasic disseminated encephalomyelitis 
(MDEM) and one with ON followed by seizures (once sec-
ondary generalized convulsion, once focal epilepsy) (Fig. 3). 
Of these 17 patients, 12 used chronic immunomodulatory 
treatment > 1 year. Seven remained on first-line treatment 
(e.g. azathioprine, mycophenolate) and five patients were 
switched to second-line treatment (e.g. rituximab n = 3, 
monthly intravenous immunoglobulins (IVIG) n = 2).
Residual neurological deficits
Overall, physicians or parents reported at least one form of 
residual deficit at the last follow-up in 162/235 (69%) ADS 
patients, including 71/86 (83%) of the MS patients, 76/133 
(57%) of the monophasic patients and 15/16 (94%) of the 
multiphasic non-MS patients. Residual neurological deficits 
were significantly more observed in MS patients compared 
to monophasic patients (p < 0.001).
In the mono-ADS group, residual deficits were most often 
present in patients with TM and NMOSD (p = 0.02). From 
the monophasic patients with a TM and residual deficits 
11/14 had suffered from a longitudinal extended transverse 
myelitis. In MS and multiphasic non-MS patients, no sig-
nificant difference was found in residual deficits between 
the presenting phenotypes.
Fig. 2  Flowchart describing the selection process
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Specific differences between the three categories were 
observed: MS patients reported significantly more sensory 
deficits and motor deficits compared to monophasic patients 
(p < 0.05) (Fig. 4). Yet in multiphasic non-MS patients vis-
ual deficits and cognitive impairment were mostly reported 
at last follow-up.
Cognitive deficits
Thirty-two percent of all included patients (78/243) under-
went an NPA (32/137 mono-ADS, 38/89 MS and 8/17 mul-
tiphasic non-MS).
At least one of the cognitive domains was affected in 65 
of the tested patients (83%), respectively, in 29/32 (91%) 
monophasic ADS, 29/38 (76%) MS and 7/8 (88%) mul-
tiphasic non-MS. Three or more cognitive domains were 
affected in 18/32 (56%) monophasic patients, 22/38 (58%) 
MS patients and in 6/8 (75%) multiphasic non-MS patients. 
The three most commonly affected domains in monophasic 
patients were intelligence, attention and concentration and 
memory, in MS patients language, attention and concen-
tration and memory and in multiphasic non-MS patients 
attention and concentration, memory and executive control 
functions. Median time till NPA from disease onset was 
15 months (IQR 6–32). In monophasic patients the median 
time was 25 months (IQR 11–62), in MS patients 11 (IQR 
6–24) and in multiphasic non-MS patients 10 (IQR 3–22).
Data on school performance were available in 216/243 
patients (monophasic patients: n = 124, MS: n = 76, 
Table 1  Presenting phenotypes and demographic characteristics
ON optic neuritis, TM transverse myelitis, ADEM acute disseminated encephalomyelitis, NMOSD neuromyelitis optica spectrum disorder, CIS 
clinically isolated syndrome, MS multiple sclerosis, MOG anti-myelin oligodendrocyte glycoproteins, AQP4 anti-aquaporin 4, IQR interquartile 
range, n number
*p value < 0.05 is considered statistically significant
a ADEM compared to the other presenting phenotypes
b TM compared to the other presenting phenotypes (excluding ADEM)
ON (n = 55) TM (n = 23) CIS monofocal 
(n = 37)
Polyfocal CIS 
(n = 47)
ADEM (n = 70) NMOSD (n = 11) p value*
Female, n (%) 30/55 (55) 15/23 (65) 23/37 (62) 29/47 (62) 35/70 (50) 7/11 (64) 0.7
Age at onset, years, 
median (IQR)
13.0 (9.6–15.8) 12.7 (4.5–16.1) 14.9 (12.0–16.2) 14.3 (9.4–15.9) 4.2 (2.6–6.1) 12.1 (9.7–16.3) < 0.001a
Reported infec-
tion < 4 weeks 
prior to first 
event, n (%)
11/52 (21) 11/22 (50) 6/34 (18) 14/45 (31) 40/69 (58) 2/11 (18) < 0.001a
0.01b
Reported vaccina-
tion < 4 weeks 
prior to first 
event, n (%)
1/53 (2) 1/22 (5) 1/36 (3) 1/43 (1) 3/69 (4) 0/11 (0) 0.9
Presence of famil-
ial autoimmune 
diseases, n (%)
26/54 (48) 9/22 (41) 21/34 (62) 18/47 (38) 33/69 (48) 7/11 (64) 0.3
Use of acute 
immunomodula-
tory treatment, 
n (%)
37/55 (67) 19/23 (83) 15/36 (42) 30/44 (68) 61/70 (87) 11/11 (100) < 0.001
Average amount 
of days in the 
hospital, median 
(IQR)
3.0 (0.0–5.0) 11.0 (5.0–22.0) 3.0 (0.0–6.5) 5.0 (0.0–10.5) 12.0 (6.8–21.0) 23.0 (5.0–23.0) < 0.001
Total MS cases, 
n (%)
23/55 (42) 5/23 (22) 30/37 (81) 30/47 (64) 1/70 (1) 0/11 (0) < 0.001
Relapsing disease, 
n (%)
23/55 (42) 4/23 (17) 25/37 (68) 27/47 (57) 8/70 (11) 3/11 (27) < 0.001
Presence of MOG 
antibodies, n (%)
4/31 (13) 1/15 (7) 1/20 (5) 3/34 (9) 17/39 (44) 5/7 (71) < 0.001
Presence of AQP4 
antibodies, n (%)
0/37 (0) 0/17 (0) 0/12 (0) 0/23 (0) 0/36 (0) 5/11 (46) < 0.001
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multiphasic non-MS patients: n = 16). Negatively affected 
school performance was reported by 63/216 (29%) of the 
participants: 37/124 (30%) of the monophasic patients, 
16/76 (21%) of the MS patients and 10/16 (63%) of the mul-
tiphasic non-MS patients. This included children to require 
academic accommodations, for instance extra assistance at 
school, extra time to complete examinations and change to 
special education.
Of those who reported negatively affected school per-
formance, 19/37 (51%) of the monophasic patients had CI 
assessed through an NPA, 7/16 (44%) of the MS patients and 
6/10 (60%) of the multiphasic non-MS patients.
Furthermore, a total of 122/243 patients reported atten-
tion deficits in the standardized questionnaire.
Disease progression in MS patients
Three of the MS patients had an EDSS of 5.5 or above at 
the last moment of follow-up. All three patients received 
acute treatment at presentation. They all presented with a 
polyfocal CIS at the first event, including brainstem as well 
as spinal involvement (n = 3). These patients had a follow-
up time of 24, 52 and 96 months and reached EDSS 5.5 at 
6, 48 and 66 months, respectively. The first patient declined 
Table 2  Follow-up characteristics of the ADS patients
MS multiple sclerosis, IQR interquartile range, MOG anti-myelin oligodendrocyte glycoprotein, AQP4 anti-aquaporin 4, n number, EDSS 
Expanded Disability Status Scale of 5.5 stands for a walking distance of about 100 m, without aid or rest
*p value < 0.05 is considered statistically significant
a Comparison between monophasic patients and MS
Monophasic disease 
(n = 137)
MS (n = 89) Multiphasic non-MS 
(n = 17)
p value*
Amount of relapses, median (IQR) n/a 2.0 (1.0–3.5) 3.0 (1.5–4.0) 0.12
Length of follow-up in months, median (IQR) 47 (22–81) 61 (38–90) 71 (32–102) 0.01
Ethnicity, n (%) < 0.001a
 European 106 (77) 44 (49) 14 (82)
 Middle-eastern 7 (5) 11 (12) 0 (0)
 African 5 (4) 19 (21) 0 (0)
 South-American 1 (1) 1 (1) 2 (12)
 Caribbean 1 (1) 3 (3) 0 (0)
 Asian 3 (2) 2 (2) 0 (0)
 Mixed 13 (10) 9 (10) 1 (6)
 Unknown 1 (1) 0 (0) 0 (0)
Use of immunomodulatory treatment > 1 year, n (%) 7/137 (5) 73/89 (82) 12/17 (71) < 0.001a
Use of second-line immunomodulatory treatment, n (%) 1/137 (1) 28/89 (32) 5/17 (29) < 0.001a
Presence of anti-MOG antibodies, n (%) 24/82 (29) 0/55 (0) 7/9 (78) < 0.001a
Presence of anti-AQP4 antibodies, n (%) 3/83 (4) 0/37 (0) 2/16 (13) 0.09a
Fig. 3  Distribution of clinical 
subtypes of patients diagnosed 
with multiphasic non-MS 
(n = 17). ADEM acute dis-
seminated encephalomyelitis, 
ON optic neuritis, NMOSD 
neuromyelitis optica spectrum 
disorder, MDEM multiphasic 
acute disseminated encephalo-
myelitis
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DMT. DMT was commenced in the other two patients, and 
both were escalated to second-line treatment (natalizumab) 
because of high MS disease activity.
Discussion
We showed that the incidence of ADS and MS is higher in 
the period of 2011–2016 than of 2007–2010 [17]. Thirty-
seven percent of the patients received a diagnosis of MS dur-
ing follow-up, which is in line with previous reports about 
the proportion of MS diagnosis in ADS. Residual deficits 
are often reported not only in MS, but in all ADS subtypes 
at last follow-up, irrespective of the presenting phenotype.
The improved awareness of ADS in The Netherlands, 
aided by a more stable and extended referral network, 
likely attributed to the increase in incidence compared to 
2007–2010. Notably, the small increase in ADS incidence 
was mainly driven by the rise in MS incidence. Our extended 
follow-up may have contributed to this higher MS incidence. 
We cannot exclude that the true incidence of paediatric MS 
is increasing in the Netherlands, as has been reported on 
overall MS incidence in other regions [18, 19]. Prolonged 
assessment of the incidence will be necessary to answer this 
question. Our new ADS incidence estimates are comparable 
to previous prospective studies that reported ADS and MS 
incidence in children [1, 24]. Moreover, our study confirms 
the skewed ethnic distribution in paediatric MS patients 
towards non-Caucasian ethnicities [1, 17, 25, 26].
A non-MS multiphasic disease course was observed in 
a minority of the patients (17/243, 7%). Remarkably 78% 
of these patients were tested seropositive for MOG-ab, in 
line with previous findings that MOG-ab positivity pleads 
against MS diagnosis and that these patients tend to have a 
relapsing disease course [27, 28].
MOG-ab and AQP4-ab seropositivity may be underesti-
mated in this cohort, as the CBAs for both antibodies were 
developed and validated after the start of our prospective 
study. Serum was not retrospectively available of every 
patient who was included before the CBAs were imple-
mented in routine diagnostics.
Over a median follow-up time of 61 months, only three 
MS patients reached an EDSS of 5.5 or above. However, 
residual neurological deficits are common in patients with 
MS (83%), in line with previous studies [11–16]. Cogni-
tive deficits are commonly encountered in MS, but are also 
described in ADEM [29, 30]. Our results show similar 
results, as 34% of the ADEM patients show CI assessed 
by an NPA. A limitation here is that only one-third of our 
patients underwent an NPA in a standardized way. As part 
of the nationwide epidemiological orientation of our study, 
testing all patients was not feasible. Still, every patient who 
underwent an NPA had at least six cognitive domains tested. 
Furthermore, since 2013, all ADEM and MS patients who 
were presented in the paediatric MS centre in Rotterdam, 
have been consecutively referred for an NPA. Therefore, 
any selection bias within these two groups would have been 
minimal, leading to a more representative view on cognitive 
impairment in these patients. Also the multiphasic non-MS 
patients reported cognitive impairment and visual problems. 
These findings can be explained by the relatively high pro-
portion of ADEM-ON patients in this group [6].
Our data further feed the impression that one single hit of 
ADEM can leave considerable intracerebral damage and may 
be considered less benign than previously thought [31–34]. 
A recent study showed reduced age-expected brain growth 
in monophasic ADS patients, especially ADEM, indicating 
irreversible and continuing changes occurring in the CNS 
even in the absence of chronicity [35]. Furthermore, recent 
studies have shown long-term residual deficits in ADEM and 
monophasic patients, such as a higher prevalence of motor 
problems, lower physical activity and fatigue [14, 15].
The high number of children with long-term residual 
deficits in the total group is concerning in relationship with 
school performances and psychomotor development, espe-
cially taking into account the cumulative nature of acquired 
disabilities after a longer disease duration in chronic demy-
elinating syndromes [9, 36]. Future participation in society, 
including work-related activities, is likely to be affected. 
Indeed, in a large proportion of adult patients, MS had neg-
atively affected their employment situation [36, 37]. These 
effects could even be worse in paediatric onset ADS. There-
fore, adequate detection and guidance of ADS patients is 
important to preserve and improve societal functioning, and 
is essential during follow-up of these patients into adulthood.
Fig. 4  Residual deficits of ADS patients at last follow-up. Definition: 
patients were classified as cognitive impaired if they had a deficit in 
at least one cognitive domain, tested by a neuropsychological assess-
ment
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There are some limitations to this study. Despite our 
quite unique and extensive national paediatric MS network 
with full geographical coverage, it is still possible that we 
have missed a few cases and thus have an underestimation 
of our incidence figures. Adolescents with CIS may have 
been assessed and followed up by an adult neurologist and, 
therefore, have not been referred to take part in our study.
In addition, the negatively affected school performance 
in ADS patients may be correlated with other problems than 
CI. Fatigue, mood disorders, anxiety and negative coping 
strategies could correlate with a negative school perfor-
mance in these patients, and may interact with cognitive 
impairment as well [14–16].
In conclusion, the reported incidence of ADS and MS 
in the Netherlands has increased during the previous years. 
Across all ADS subtypes the observed residual neurologi-
cal deficits are considerable. Long-term follow-up studies 
of ADS patients will be needed to provide more insight into 
the risks involved and to identify possibilities for timely 
intervention.
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